JP2017505316A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505316A5
JP2017505316A5 JP2016549493A JP2016549493A JP2017505316A5 JP 2017505316 A5 JP2017505316 A5 JP 2017505316A5 JP 2016549493 A JP2016549493 A JP 2016549493A JP 2016549493 A JP2016549493 A JP 2016549493A JP 2017505316 A5 JP2017505316 A5 JP 2017505316A5
Authority
JP
Japan
Prior art keywords
antipsychotic drug
vmat2 inhibitor
effective amount
therapeutically effective
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549493A
Other languages
English (en)
Japanese (ja)
Other versions
JP6718376B2 (ja
JP2017505316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/014893 external-priority patent/WO2015120317A1/en
Publication of JP2017505316A publication Critical patent/JP2017505316A/ja
Publication of JP2017505316A5 publication Critical patent/JP2017505316A5/ja
Application granted granted Critical
Publication of JP6718376B2 publication Critical patent/JP6718376B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549493A 2014-02-07 2015-02-06 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用 Expired - Fee Related JP6718376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937223P 2014-02-07 2014-02-07
US61/937,223 2014-02-07
PCT/US2015/014893 WO2015120317A1 (en) 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087459A Division JP2019116515A (ja) 2014-02-07 2019-05-07 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2017505316A JP2017505316A (ja) 2017-02-16
JP2017505316A5 true JP2017505316A5 (https=) 2018-03-22
JP6718376B2 JP6718376B2 (ja) 2020-07-08

Family

ID=52589782

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549493A Expired - Fee Related JP6718376B2 (ja) 2014-02-07 2015-02-06 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
JP2019087459A Withdrawn JP2019116515A (ja) 2014-02-07 2019-05-07 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
JP2021032320A Pending JP2021080294A (ja) 2014-02-07 2021-03-02 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
JP2023195803A Pending JP2024003253A (ja) 2014-02-07 2023-11-17 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019087459A Withdrawn JP2019116515A (ja) 2014-02-07 2019-05-07 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
JP2021032320A Pending JP2021080294A (ja) 2014-02-07 2021-03-02 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
JP2023195803A Pending JP2024003253A (ja) 2014-02-07 2023-11-17 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Country Status (13)

Country Link
US (4) US9782398B2 (https=)
EP (2) EP4049681B1 (https=)
JP (4) JP6718376B2 (https=)
KR (1) KR102328058B1 (https=)
CN (3) CN113368110A (https=)
AU (1) AU2015213778B2 (https=)
CA (1) CA2938581C (https=)
ES (1) ES3062021T3 (https=)
IL (1) IL247127B (https=)
MX (1) MX378664B (https=)
NZ (2) NZ760790A (https=)
RU (2) RU2757221C2 (https=)
WO (1) WO2015120317A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
CA2974540C (en) * 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
ES2991518T3 (es) * 2018-05-04 2024-12-03 Korea Inst Radiological & Medical Sciences Composición para la mejora de la sensibilidad a la radiación que contiene aripiprazol como ingrediente activo
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020188551A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for treating autism spectrum disorder and associated disorders
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
BR112023026691A2 (pt) * 2021-06-30 2024-03-05 Neurocrine Biosciences Inc Valbenazina para uso no tratamento complementar de esquizofrenia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
AU1321900A (en) * 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1855677B1 (en) * 2005-08-06 2008-12-03 Cambridge Laboratories (Ireland) Limited 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
PL2081929T3 (pl) * 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2

Similar Documents

Publication Publication Date Title
JP2017505316A5 (https=)
RU2016135930A (ru) Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
JP2019182877A (ja) 細菌感染の治療薬
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
CU20170154A7 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk
JP2017503842A5 (https=)
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
JP2014114295A5 (https=)
JP2015537003A5 (https=)
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UA117260C2 (uk) Лікарський препарат з відстроченим вивільненням
ECSP11011403A (es) Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2017513925A (ja) 徐放性ブプレノルフィン溶液
FI3970707T3 (fi) Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon
JP2015506359A5 (https=)
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
KR101780739B1 (ko) 활성성분-함유 필름 코팅층을 포함하는 복합제제
GT201300144A (es) Composiciones farmaceuticas
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
KR20230116836A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
CA2902823A1 (en) Intrathecal hydromorphone solutions having improved stability
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
JP2015504094A5 (https=)